Dynamic contrast-enhanced MR imaging of carotid atherosclerotic plaque: model selection, reproducibility, and validation.

PURPOSE To compare four known pharmacokinetic models for their ability to describe dynamic contrast material-enhanced magnetic resonance (MR) imaging of carotid atherosclerotic plaques, to determine reproducibility, and to validate the results with histologic findings. MATERIALS AND METHODS The study was approved by the institutional medical ethics committee. Written informed consent was obtained from all patients. Forty-five patients with 30%-99% carotid stenosis underwent dynamic contrast-enhanced MR imaging. Plaque enhancement was measured at 16 time points at approximately 25-second image intervals by using a gadolinium-based contrast material. Pharmacokinetic parameters (volume transfer constant, K(trans); extracellular extravascular volume fraction, v(e); and blood plasma fraction, v(p)) were determined by fitting a two-compartment model to plaque and blood gadolinium concentration curves. The relative fit errors and parameter uncertainties were determined to find the most suitable model. Sixteen patients underwent imaging twice to determine reproducibility. Carotid endarterectomy specimens from 16 patients who were scheduled for surgery were collected for histologic validation. Parameter uncertainties were compared with the Wilcoxon signed rank test. Reproducibility was assessed by using the coefficient of variation. Correlation with histologic findings was evaluated with the Pearson correlation coefficient. RESULTS The mean relative fit uncertainty (±standard error) for K(trans) was 10% ± 1 with the Patlak model, which was significantly lower than that with the Tofts (20% ± 1), extended Tofts (33% ± 3), and extended graphical (29% ± 3) models (P < .001). The relative uncertainty for v(p) was 20% ± 2 with the Patlak model and was significantly higher with the extended Tofts (46% ± 9) and extended graphical (35% ± 5) models (P < .001). The reproducibility (coefficient of variation) for the Patlak model was 16% for K(trans) and 26% for v(p). Significant positive correlations were found between K(trans) and the endothelial microvessel content determined on histologic slices (Pearson ρ = 0.72, P = .005). CONCLUSION The Patlak model is most suited for describing carotid plaque enhancement. Correlation with histologic findings validated K(trans) as an indicator of plaque microvasculature, and the reproducibility of K(trans) was good.

[1]  M. E. Kooi,et al.  Carotid Plaques in Transient Ischemic Attack and Stroke Patients: One-Year Follow-up Study by Magnetic Resonance Imaging , 2010, Investigative radiology.

[2]  David L Buckley,et al.  Uncertainty in the analysis of tracer kinetics using dynamic contrast‐enhanced T1‐weighted MRI , 2002, Magnetic resonance in medicine.

[3]  J M Bland,et al.  Statistical methods for assessing agreement between two methods of clinical measurement , 1986 .

[4]  J. V. van Engelshoven,et al.  Symptomatic Patients With Mild and Moderate Carotid Stenosis: Plaque Features at MRI and Association With Cardiovascular Risk Factors and Statin Use , 2010, Stroke.

[5]  Mathijs Groeneweg,et al.  Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. , 2008, Journal of the American College of Cardiology.

[6]  Chun Yuan,et al.  Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. , 2006, Radiology.

[7]  George A. Mensah,et al.  The atlas of heart disease and stroke , 2005 .

[8]  J. V. van Engelshoven,et al.  Multimodality Imaging of Carotid Artery Plaques: 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging , 2009, Stroke.

[9]  Chun Yuan,et al.  In vivo accuracy of multisequence MR imaging for identifying unstable fibrous caps in advanced human carotid plaques , 2003, Journal of magnetic resonance imaging : JMRI.

[10]  N A W van Riel,et al.  System identification theory in pharmacokinetic modeling of dynamic contrast‐enhanced MRI: Influence of contrast injection , 2008, Magnetic resonance in medicine.

[11]  T. Leiner,et al.  Optimized pharmacokinetic modeling for the detection of perfusion differences in skeletal muscle with DCE-MRI: effect of contrast agent size. , 2010, Medical physics.

[12]  Natal A W van Riel,et al.  On the identifiability of pharmacokinetic parameters in dynamic contrast‐enhanced imaging , 2007, Magnetic resonance in medicine.

[13]  Antonio Colombo,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.

[14]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.

[15]  Aloke V. Finn,et al.  Atherosclerotic Plaque Progression and Vulnerability to Rupture: Angiogenesis as a Source of Intraplaque Hemorrhage , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[16]  D. Altman,et al.  Measurement error. , 1996, BMJ.

[17]  Renu Virmani,et al.  Intraplaque hemorrhage and progression of coronary atheroma. , 2003, The New England journal of medicine.

[18]  Chun Yuan,et al.  In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. , 2002 .

[19]  P. Tofts Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[20]  Thomas E. Feasby,et al.  Carotid endarterectomy - An evidence-based review: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2008 .

[21]  S. Gutnikov,et al.  Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis , 2003, The Lancet.

[22]  R. R. Ernst,et al.  Application of Fourier Transform Spectroscopy to Magnetic Resonance , 1966 .

[23]  Tim Leiner,et al.  Reliability of pharmacokinetic parameters: Small vs. medium‐sized contrast agents , 2009, Magnetic resonance in medicine.

[24]  Claudia Calcagno,et al.  Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis , 2010, Angiogenesis.

[25]  A. Jackson,et al.  Experimentally‐derived functional form for a population‐averaged high‐temporal‐resolution arterial input function for dynamic contrast‐enhanced MRI , 2006, Magnetic resonance in medicine.

[26]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[27]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[28]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  W S Kerwin,et al.  MR imaging of adventitial vasa vasorum in carotid atherosclerosis , 2008, Magnetic resonance in medicine.

[30]  R. Ross Atherosclerosis is an inflammatory disease , 1999 .

[31]  R. Holloway,et al.  Carotid endarterectomy—An evidence-based review , 2005, Neurology.

[32]  R Eugene Zierler,et al.  Carotid artery stenosis: gray-scale and Doppler US diagnosis--Society of Radiologists in Ultrasound Consensus Conference. , 2003, Radiology.

[33]  Chun Yuan,et al.  Quantitative Magnetic Resonance Imaging Analysis of Neovasculature Volume in Carotid Atherosclerotic Plaque , 2003, Circulation.

[34]  M. Eliasziw,et al.  Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery , 2004, The Lancet.

[35]  Chun Yuan,et al.  Extended graphical model for analysis of dynamic contrast‐enhanced MRI , 2011, Magnetic resonance in medicine.